1. Home
  2. SHFS vs CDT Comparison

SHFS vs CDT Comparison

Compare SHFS & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SHF Holdings Inc.

SHFS

SHF Holdings Inc.

HOLD

Current Price

$0.83

Market Cap

3.0M

Sector

Finance

ML Signal

HOLD

Logo Conduit Pharmaceuticals Inc.

CDT

Conduit Pharmaceuticals Inc.

HOLD

Current Price

$0.65

Market Cap

2.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SHFS
CDT
Founded
2015
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0M
2.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SHFS
CDT
Price
$0.83
$0.65
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
62.5K
311.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$0.37
52 Week High
$9.18
$6.00

Technical Indicators

Market Signals
Indicator
SHFS
CDT
Relative Strength Index (RSI) 39.64 32.77
Support Level $0.84 $0.53
Resistance Level $1.03 $1.16
Average True Range (ATR) 0.09 0.11
MACD 0.00 0.00
Stochastic Oscillator 40.73 13.74

Price Performance

Historical Comparison
SHFS
CDT

About SHFS SHF Holdings Inc.

SHF Holdings Inc is a financial services provider to cannabis-related businesses. It offers reliable access to banking solutions for cannabis, hemp, CBD, and ancillary operators, making communities safer, driving growth in local economies, and fostering long-term partnerships. The group, through its financial institution clients, implements accountability, transparency, monitoring, reporting, and risk mitigation measures while meeting Bank Secrecy Act obligations in line with FinCEN guidance on cannabis-related businesses. Its services include Program Management Support, Customer Generation, Ongoing Program Auditing, and Compliance Monitoring, among others.

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Share on Social Networks: